Starpharma Stock Forecast, Price & News

-1.30 (-7.98 %)
(As of 04/12/2021 12:00 AM ET)
Today's Range
Now: $15.00
50-Day Range
MA: $15.74
52-Week Range
Now: $15.00
Volume759 shs
Average Volume3,811 shs
Market Capitalization$609.03 million
P/E RatioN/A
Dividend YieldN/A
Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase 1 clinical trial, and DEP irinotecan that is in phase 1/2 clinical trials for the treatment of solid tumors. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Starpharma logo

Industry, Sector and Symbol

Industry Commercial physical research
Year FoundedN/A



Sales & Book Value

Annual Sales$4.40 million
Book Value$0.56 per share



Market Cap$609.03 million
Next Earnings DateN/A
OptionableNot Optionable


Critical Survey: Starpharma (OTCMKTS:SPHRY) vs. PPD (NASDAQ:PPD)
March 31, 2021 |  americanbankingnews.com
Our Take On Starpharma Holdings' (ASX:SPL) CEO Salary
December 3, 2020 |  finance.yahoo.com
A Neglected Treatment Space For COVID-19
August 6, 2020 |  seekingalpha.com
Starpharma's SPL7013 Antiviral Takes On COVID-19
May 4, 2020 |  seekingalpha.com
Starpharma to develop COVID-19 treatment
April 16, 2020 |  seekingalpha.com
See More Headlines


Overall MarketRank

0.46 out of 5 stars

Medical Sector

1676th out of 2,016 stocks

Commercial Physical Research Industry

34th out of 42 stocks

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
-1.30 (-7.98 %)
(As of 04/12/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SPHRY News and Ratings via Email

Sign-up to receive the latest news and ratings for SPHRY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Starpharma (OTCMKTS:SPHRY) Frequently Asked Questions

What stocks does MarketBeat like better than Starpharma?

Wall Street analysts have given Starpharma a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Starpharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Starpharma?

Starpharma saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 900 shares, an increase of 800.0% from the February 28th total of 100 shares. Based on an average daily trading volume, of 3,400 shares, the short-interest ratio is presently 0.3 days.
View Starpharma's Short Interest

How has Starpharma's stock price been impacted by COVID-19 (Coronavirus)?

Starpharma's stock was trading at $6.22 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SPHRY stock has increased by 141.2% and is now trading at $15.00.
View which stocks have been most impacted by COVID-19

Who are Starpharma's key executives?

Starpharma's management team includes the following people:
  • Dr. Jacinth K. Fairley B.Sc., B.V.Sc.(Hons), MBA, GAICD, CEO, MD & Exec. Director (Age 58)
  • Mr. Nigel J. Baade B.Com, Grad. Dip., CPA, CFO & Company Sec.

Who are some of Starpharma's key competitors?

What is Starpharma's stock symbol?

Starpharma trades on the OTCMKTS under the ticker symbol "SPHRY."

How do I buy shares of Starpharma?

Shares of SPHRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Starpharma's stock price today?

One share of SPHRY stock can currently be purchased for approximately $15.00.

How much money does Starpharma make?

Starpharma has a market capitalization of $609.03 million and generates $4.40 million in revenue each year.

What is Starpharma's official website?

The official website for Starpharma is www.starpharma.com.

Where are Starpharma's headquarters?

Starpharma is headquartered at 4-6 Southampton Crescent, Abbotsford C3, 3072.

How can I contact Starpharma?

Starpharma's mailing address is 4-6 Southampton Crescent, Abbotsford C3, 3072. The company can be reached via phone at 61-3-8532-2700 or via email at [email protected]

This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.